Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT04896658 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT04896658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04896658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1/2
Overall status
Terminated
Start date
December 3, 2021
Completion date
December 1, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma